Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Esperion Therapeutics Q1 EPS $0.34 Beats $0.05 Estimate, Sales $137.74M Beat $84.51M Estimate

Author: Benzinga Newsdesk | May 07, 2024 06:02am
Esperion Therapeutics (NASDAQ:ESPR) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.05 by 580 percent. This is a 143.04 percent increase over losses of $(0.79) per share from the same period last year. The company reported quarterly sales of $137.74 million which beat the analyst consensus estimate of $84.51 million by 62.98 percent. This is a 466.14 percent increase over sales of $24.33 million the same period last year.

Posted In: ESPR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist